Faze Medicines is using the latest research in biomolecular condensates to pioneer novel therapeutics. Biomolecular condensates are membraneless organelles that play key roles in the healthy functioning of cells. The condensates can contain both protein and DNA and help organize cellular processes. Dysfunction in their assembly caused by genetic mutations has been connected to many neurological diseases, including frontotemporal dementia and ALS, and leads to protein aggregation. Faze is identifying and targeting key regulators of the condensates with small molecules to prevent aggregation through screening and proteomics techniques. Faze’s initial therapeutic focus area is ALS and myotonic dystrophy.
Claim company profile to post jobs directly on this page and this website.